Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Practice of Molecular Radiotherapy

Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies

Robert M. Sharkey and David M. Goldenberg
Journal of Nuclear Medicine January 2005, 46 (1 suppl) 115S-127S;
Robert M. Sharkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Goldenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

FIGURE 2.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Schematic representation of various forms of antibody fragments prepared by enzymatic digestion or molecular engineering. The most commonly used form of antibody, IgG, has been radiolabeled by conjugating directly to the protein (e.g., radioiodination of tyrosine) or radiolabeling a coupled chelator. Chelators have been coupled directly to the protein or to the carbohydrates that reside on the Fc-portion of the molecule. Single chains are formed by linking the variable light (VL) and variable heavy (VH) chains with amino acid (AA) linker. Diabodies, triabodies, and even tetrabodies are formed spontaneously when smaller length AA chains are used to hold the VH and VL units together. Recombinant bispecific diabodies and other bispecific constructs can be prepared by pairing VH and VL of 2 antibodies with different specificities.

  View article

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FIGURE 2.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
Robert M. Sharkey, David M. Goldenberg
Journal of Nuclear Medicine Jan 2005, 46 (1 suppl) 115S-127S;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
Robert M. Sharkey, David M. Goldenberg
Journal of Nuclear Medicine Jan 2005, 46 (1 suppl) 115S-127S;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment
  • Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
  • Treatment of Early and Established Cryptococcus neoformans Infection with Radiolabeled Antibodies in Immunocompetent Mice
  • Antitumor Effects of a Human Dimeric Antibody Fragment 131I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer
  • Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
  • Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
  • Targeting of drugs and nanoparticles to tumors
  • Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model
  • Radiolabeled Antibodies to Bacillus anthracis Toxins Are Bactericidal and Partially Therapeutic in Experimental Murine Anthrax
  • Some like it hot: lymphoma radioimmunotherapy
  • A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
  • A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
  • Radioimmunotherapy of Experimental Human Metastatic Melanoma with Melanin-Binding Antibodies and in Combination with Dacarbazine
  • Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model
  • Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
  • Adjuvant and Combined Radioimmunotherapy: Problems and Prospects on the Road to Minerva
  • Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
  • Radioimmunotherapy Against the Tumor Vasculature: A New Target?
  • Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease?
  • Enhanced Efficacy of 90Y-Radiolabeled Anti-Lewis Y Humanized Monoclonal Antibody hu3S193 and Paclitaxel Combined-Modality Radioimmunotherapy in a Breast Cancer Model
  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
  • Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size?
  • 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab
  • Google Scholar

More in this TOC Section

  • Current Status of Therapy of Solid Tumors
  • The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma
  • Current Status of Therapy of Solid Tumors: Brain Tumor Therapy
Show more Clinical Practice of Molecular Radiotherapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire